LIVIVO - Search results -

Search results

Result 1 - 10 of total 37

Search options

Article ; Online: Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: An observational study in routine clinical care.

Naniwa, Taio / Iwagaitsu, Shiho / Kajiura, Mikiko

2020 Volume 30, Issue 6, Page(s) 948–958

Abstract: Objectives: ...

Abstract	Objectives:
MeSH term(s)	Adult ; Antirheumatic Agents/administration & dosage ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Disease Progression ; Drug Administration Schedule ; Female ; Humans ; Male ; Methotrexate/administration & dosage ; Methotrexate/therapeutic use ; Middle Aged ; Tumor Necrosis Factor Inhibitors/administration & dosage ; Tumor Necrosis Factor Inhibitors/therapeutic use
Chemical Substances	Antirheumatic Agents ; Tumor Necrosis Factor Inhibitors ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2020-01-21
Publishing country	United States
Document type	Journal Article ; Observational Study
ZDB-ID	2078157-X
ISSN	1439-7609 ; 1439-7595
ISSN (online)	1439-7609
ISSN	1439-7595
DOI	10.1080/14397595.2019.1702253
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2982: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Improvement of Arterial Wall Lesions in Parallel with Decrease of Plasma Pentraxin-3 Levels in a Patient with Refractory Takayasu Arteritis after Treatment with Tocilizumab.

Iwagaitsu, Shiho / Naniwa, Taio

Case reports in rheumatology

2017 Volume 2017, Page(s) 4580967

Abstract: A 19-year-old Japanese woman with active Takayasu arteritis despite multiple conventional immunosuppressive therapies with glucocorticoids in combination with intravenous cyclophosphamide, azathioprine, or infliximab with methotrexate and tacrolimus was ... ...

Abstract	A 19-year-old Japanese woman with active Takayasu arteritis despite multiple conventional immunosuppressive therapies with glucocorticoids in combination with intravenous cyclophosphamide, azathioprine, or infliximab with methotrexate and tacrolimus was successfully treated by switching from infliximab to intravenous tocilizumab. Worsening of claudication of the legs and elevated acute phase reactants, including plasma pentraxin-3 levels, were observed during combination therapy with infliximab. Computed tomography demonstrated increased wall thickening with contrast enhancement in the preexisting lesion of the descending aorta and the femoral arteries. After switching from infliximab to tocilizumab, plasma pentraxin-3 levels gradually decreased to the normal range in parallel with the improvement of claudication. Follow-up computed tomographic scans confirmed the marked improvement of these arterial lesions. Moreover, plasma pentraxin-3 level was increased in response to the worsening of claudication that occurred just after switching to a subcutaneous tocilizumab injection. Measurements of plasma pentraxin-3 might be useful for evaluation of the vascular wall inflammation and therapeutic efficacy even during biologic therapy targeting tumor necrosis factor
Language	English
Publishing date	2017-06-06
Publishing country	United States
Document type	Case Reports
ZDB-ID	2666708-3
ISSN	2090-6897 ; 2090-6889
ISSN (online)	2090-6897
ISSN	2090-6889
DOI	10.1155/2017/4580967
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Improvement of Arterial Wall Lesions in Parallel with Decrease of Plasma Pentraxin-3 Levels in a Patient with Refractory Takayasu Arteritis after Treatment with Tocilizumab

Shiho Iwagaitsu / Taio Naniwa

Case Reports in Rheumatology, Vol

2017 Volume 2017

Abstract	A 19-year-old Japanese woman with active Takayasu arteritis despite multiple conventional immunosuppressive therapies with glucocorticoids in combination with intravenous cyclophosphamide, azathioprine, or infliximab with methotrexate and tacrolimus was successfully treated by switching from infliximab to intravenous tocilizumab. Worsening of claudication of the legs and elevated acute phase reactants, including plasma pentraxin-3 levels, were observed during combination therapy with infliximab. Computed tomography demonstrated increased wall thickening with contrast enhancement in the preexisting lesion of the descending aorta and the femoral arteries. After switching from infliximab to tocilizumab, plasma pentraxin-3 levels gradually decreased to the normal range in parallel with the improvement of claudication. Follow-up computed tomographic scans confirmed the marked improvement of these arterial lesions. Moreover, plasma pentraxin-3 level was increased in response to the worsening of claudication that occurred just after switching to a subcutaneous tocilizumab injection. Measurements of plasma pentraxin-3 might be useful for evaluation of the vascular wall inflammation and therapeutic efficacy even during biologic therapy targeting tumor necrosis factor α and interleukin-6.
Keywords	Internal medicine ; RC31-1245 ; Diseases of the musculoskeletal system ; RC925-935
Subject code	610
Language	English
Publishing date	2017-01-01T00:00:00Z
Publisher	Hindawi Publishing Corporation
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.

Naniwa, Taio / Iwagaitsu, Shiho / Kajiura, Mikiko

International journal of rheumatic diseases

2018 Volume 21, Issue 3, Page(s) 673–687

Abstract: Aim: To assess the long-term efficacy and safety of adding tacrolimus for patients with active rheumatoid arthritis (RA) despite anti-tumor necrosis factor (TNF) therapy with methotrexate.: Methods: Consecutive patients who were treated with adding ... ...

Abstract	Aim: To assess the long-term efficacy and safety of adding tacrolimus for patients with active rheumatoid arthritis (RA) despite anti-tumor necrosis factor (TNF) therapy with methotrexate. Methods: Consecutive patients who were treated with adding tacrolimus onto anti-TNF therapy with methotrexate for active RA despite anti-TNF therapy with methotrexate, were retrospectively analyzed in terms of treatment response, achieving remission, subsequent treatment tapering and adverse events. Results: Fifteen patients could be analyzed. Median symptom duration was 2.9 years and prior duration of anti-TNF therapy was 40 weeks. Median value of Disease Activity Score in 28 joints was 4.6. Five, eight and two were on infliximab, etanercept and adalimumab at the onset of tacrolimus, respectively. At 2 years, the proportions of patients achieving responses of American College of Rheumatology 50, 70 and 90, were 80%, 73% and 40%, respectively, and those achieving remission as defined by Simplified Disease Activity Index ≤ 3.3 were 67%. All patients could discontinue oral glucocorticoids and 10 had been successfully withdrawn from anti-TNF therapy for more than 1 year at the final observation. Conclusion: Adding tacrolimus onto anti-TNF therapy is a promising therapeutic option with sustained benefit for refractory RA patients despite treatment with anti-TNF therapy combined with methotrexate.
MeSH term(s)	Aged ; Antirheumatic Agents/adverse effects ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/diagnostic imaging ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/immunology ; Biological Products/adverse effects ; Biological Products/therapeutic use ; Drug Therapy, Combination ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Male ; Methotrexate/adverse effects ; Methotrexate/therapeutic use ; Middle Aged ; Remission Induction ; Retrospective Studies ; Tacrolimus/adverse effects ; Tacrolimus/therapeutic use ; Time Factors ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/immunology
Chemical Substances	Antirheumatic Agents ; Biological Products ; Immunosuppressive Agents ; Tumor Necrosis Factor-alpha ; Tacrolimus (WM0HAQ4WNM) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2018-01-04
Publishing country	England
Document type	Journal Article
ZDB-ID	2426924-4
ISSN	1756-185X ; 1756-1841
ISSN (online)	1756-185X
ISSN	1756-1841
DOI	10.1111/1756-185X.13248
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6098: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Case report: Thrombotic microangiopathy concomitant with macrophage activation syndrome in systemic lupus erythematosus refractory to conventional treatment successfully treated with eculizumab.

Yamaguchi, Makoto / Mizuno, Masashi / Kitamura, Fumiya / Iwagaitsu, Shiho / Nobata, Hironobu / Kinashi, Hiroshi / Banno, Shogo / Asai, Akimasa / Ishimoto, Takuji / Katsuno, Takayuki / Ito, Yasuhiko

Frontiers in medicine

2023 Volume 9, Page(s) 1097528

Abstract: Thrombotic microangiopathy (TMA) is a rare but life-threatening complication of systemic lupus erythematosus (SLE). Macrophage activation syndrome (MAS) is also a rare, life-threatening hyperinflammatory condition that is comorbid with SLE. However, the ... ...

Abstract	Thrombotic microangiopathy (TMA) is a rare but life-threatening complication of systemic lupus erythematosus (SLE). Macrophage activation syndrome (MAS) is also a rare, life-threatening hyperinflammatory condition that is comorbid with SLE. However, the association between TMA and MAS in patients with SLE has rarely been assessed, and the difficulty of diagnosing these conditions remains prevalent. The efficacy of eculizumab has been reported for SLE patients whose conditions are complicated with TMA. However, no study has investigated the therapeutic efficacy of eculizumab for TMA concomitant with SLE-associated MAS. Herein, we report the first case of TMA concomitant with SLE-associated MAS that was initially refractory to conventional immunosuppressive therapy but showed remarkable recovery after eculizumab treatment. Furthermore, we evaluated serum syndecan-1 and hyaluronan levels, which are biomarkers of endothelial damage. We found that these levels decreased after the administration of eculizumab, suggesting that TMA was the main pathology of the patient. This case illustrates that it is important to appropriately assess the possibility of TMA during the course of SLE-associated MAS and consider the use of eculizumab as necessary.
Language	English
Publishing date	2023-01-09
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	2775999-4
ISSN	2296-858X
ISSN	2296-858X
DOI	10.3389/fmed.2022.1097528
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Malnutrition according to the GLIM criteria with kidney dysfunction is associated with increased mortality in hospitalized patients with cardiovascular disease: A retrospective cohort study.

Yamaguchi, Makoto / Ito, Mayumi / Sugiyama, Hirokazu / Iwagaitsu, Shiho / Nobata, Hironobu / Kinashi, Hiroshi / Katsuno, Takayuki / Banno, Shogo / Ito, Yasuhiko / Ando, Masahiko / Kubo, Yoko / Maeda, Keisuke / Ishida, Yuria / Mori, Naoharu / Ishimoto, Takuji

Clinical nutrition ESPEN

2023 Volume 55, Page(s) 167–173

Abstract: Background & aims: Cardiovascular disease (CVD) is a significant cause of mortality and rising healthcare costs, involving numerous chronic and nutritional risk. Although several studies have reported that malnutrition based on the Global Leadership ... ...

Abstract	Background & aims: Cardiovascular disease (CVD) is a significant cause of mortality and rising healthcare costs, involving numerous chronic and nutritional risk. Although several studies have reported that malnutrition based on the Global Leadership Initiative on Malnutrition (GLIM) criteria is associated with mortality in patients with CVD, they have not evaluated this association in terms of malnutrition severity (moderate or severe). Furthermore, the relationship between malnutrition combined with renal dysfunction, a risk factor for death in CVD patients, and mortality has not been previously evaluated. Thus, we aimed to assess the association between malnutrition severity and mortality, as well as malnutrition status stratified by kidney function and mortality, in patients hospitalized due to CVD events. Methods: This single-centre, retrospective cohort study included 621 patients with CVD aged ≥18 years admitted to Aichi Medical University between 2019 and 2020. The relationship between nutritional status based on the GLIM criteria (without malnutrition, moderate malnutrition, or severe malnutrition) and the incidence of all-cause mortality was evaluated by multivariable Cox proportional hazards models. Results: Patients with moderate and severe malnutrition were significantly more prone to mortality than those without malnutrition (adjusted hazard ratio [HR] of patients without, with moderate, and with severe malnutrition: 1.00 [reference], 1.94 [1.12-3.35], and 2.63 [1.53-4.50], respectively). Furthermore, we found the highest all-cause mortality rate in patients with malnutrition and a lower estimated glomerular filtration rate (eGFR <30 mL/min/1.73 m Conclusions: The present study indicated that malnutrition according to the GLIM criteria was associated with increased all-cause mortality in patients with CVD, and malnutrition associated with kidney dysfunction was associated with a higher risk of mortality. These findings provide clinically relevant information to identify high mortality risk in patients with CVD and highlight the need for giving careful attention to malnutrition with kidney dysfunction among patients with CVD.
MeSH term(s)	Humans ; Adolescent ; Adult ; Cardiovascular Diseases/complications ; Leadership ; Retrospective Studies ; Malnutrition/complications ; Kidney
Language	English
Publishing date	2023-03-03
Publishing country	England
Document type	Journal Article
ISSN	2405-4577
ISSN (online)	2405-4577
DOI	10.1016/j.clnesp.2023.02.029
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Association between statin use and incidence of relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-center retrospective cohort study.

Yamaguchi, Makoto / Katsuno, Takayuki / Iwagaitsu, Shiho / Nobata, Hironobu / Kinashi, Hiroshi / Banno, Shogo / Ito, Yasuhiko

Rheumatology international

2020 Volume 40, Issue 8, Page(s) 1291–1299

Abstract: Several studies have shown the efficacy of statins for some autoimmune disorders caused by anti-inflammatory and immunomodulatory reactions. However, little information is available about the impact of statins on relapse in antineutrophil cytoplasmic ... ...

Abstract	Several studies have shown the efficacy of statins for some autoimmune disorders caused by anti-inflammatory and immunomodulatory reactions. However, little information is available about the impact of statins on relapse in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). We performed the first investigation examining whether statin use has an effect on suppressing the first relapse of AAV in Japanese patients with AAV. This single-center retrospective cohort study included 98 consecutive patients with newly diagnosed AAV from Aichi Medical University Hospital, Japan between March 2009 and December 2017. Time to first relapse from the first remission was compared between 36 patients in the statin group and 62 patients in the non-statin group using multivariate Cox proportional hazard models, which were adjusted for clinically relevant factors. During the follow-up period (median, 24 months; interquartile range, 9-50 months), 35 (97.2%) patients in the statin group achieved remission, whereas 56 (90.3%) patients achieved remission in the non-statin group (P = 0.201). After achieving the first remission, 9 (25.7%) patients in the statin group and 29 (51.8%) patients in the non-statin group had at least one relapse. Multivariate Cox proportional hazard models revealed that statin use was significantly associated with a lower incidence of relapse compared with non-statin use (multivariate-adjusted hazard ratio = 0.41, 95% confidence interval: 0.18-0.92; P = 0.031). Patients with statin use were associated with a lower incidence of relapse in AAV. Our results should be assessed in well-designed randomized controlled trials.
MeSH term(s)	Aged ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/immunology ; Case-Control Studies ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Japan ; Male ; Middle Aged ; Proportional Hazards Models ; Recurrence ; Remission Induction/methods ; Retrospective Studies ; Time Factors
Chemical Substances	Hydroxymethylglutaryl-CoA Reductase Inhibitors
Language	English
Publishing date	2020-03-28
Publishing country	Germany
Document type	Journal Article ; Observational Study
ZDB-ID	8286-7
ISSN	1437-160X ; 0172-8172
ISSN (online)	1437-160X
ISSN	0172-8172
DOI	10.1007/s00296-020-04562-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1639: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor inhibitor due to clinical remission.

Naniwa, Taio / Iwagaitsu, Shiho / Kajiura, Mikiko

Modern rheumatology

2017 Volume 27, Issue 1, Page(s) 29–34

Abstract: Objectives: To describe the efficacy of adding tacrolimus to maintain remission in patients with rheumatoid arthritis (RA) on methotrexate after discontinuation of tumor necrosis factor inhibitor (TNFi) therapy.: Methods: Consecutive patients with RA, ...

Abstract	Objectives: To describe the efficacy of adding tacrolimus to maintain remission in patients with rheumatoid arthritis (RA) on methotrexate after discontinuation of tumor necrosis factor inhibitor (TNFi) therapy. Methods: Consecutive patients with RA, who resumed a TNFi to treat flares after initial TNFi-free remission and discontinued a TNFi again after achieving remission and adding tacrolimus were enrolled. The lengths of remission after discontinuation of TNFi without or with tacrolimus were analyzed. Results: Thirteen TNFi-free periods in six patients, in which seven were without and six were with tacrolimus were analyzed. All were seropositive females with a median age of 46 years and symptom duration of 1.2 years at the onset of TNFi therapy. Two were treated with infliximab and four were with etanercept. The median dose of tacrolimus was 2 mg/day with trough level of 4.5 ng/ml. The length of time to flare after discontinuation of TNFi therapy with tacrolimus was significantly longer than those without tacrolimus (median 107 weeks [range 4-207] versus 13 weeks [2-36]). After adding tacrolimus, only one patient resumed TNFi therapy and three had no flare until final observation. Conclusions: Add-on tacrolimus was effective in maintaining TNFi-free remission in patients with RA who ever relapsed after TNFi-free remission.
MeSH term(s)	Adult ; Antirheumatic Agents/administration & dosage ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/drug therapy ; Drug Monitoring ; Etanercept/administration & dosage ; Female ; Humans ; Infliximab/administration & dosage ; Japan ; Longitudinal Studies ; Male ; Medication Therapy Management/statistics & numerical data ; Methotrexate/administration & dosage ; Middle Aged ; Remission Induction/methods ; Tacrolimus/administration & dosage ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Withholding Treatment/statistics & numerical data
Chemical Substances	Antirheumatic Agents ; Tumor Necrosis Factor-alpha ; Infliximab (B72HH48FLU) ; Etanercept (OP401G7OJC) ; Tacrolimus (WM0HAQ4WNM) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2017-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	2078157-X
ISSN	1439-7609 ; 1439-7595
ISSN (online)	1439-7609
ISSN	1439-7595
DOI	10.3109/14397595.2016.1174394
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2982: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A case of 2,8-DHA crystalline nephropathy caused by adenine phosphoribosyltransferase deficiency: diagnosis and treatment.

Kunou, Miyoko / Yamaguchi, Makoto / Takahashi, Hirotake / Kimura, Yukihiro / Watanabe, Naoki / Ito, Mayumi / Sugiyama, Hirokazu / Iwagaitsu, Shiho / Nobata, Hironobu / Kinashi, Hiroshi / Katsuno, Takayuki / Banno, Shogo / Ito, Yasuhiko / Ishimoto, Takuji

CEN case reports

2022 Volume 12, Issue 3, Page(s) 329–334

Abstract: Adenine phosphoribosyltransferase (APRT) deficiency is a rare autosomal recessive disorder that leads to the accumulation of poorly soluble 2,8-dihydroxyadenine (DHA) in the kidneys, resulting in a variety of renal presentations including nephrolithiasis, ...

Abstract	Adenine phosphoribosyltransferase (APRT) deficiency is a rare autosomal recessive disorder that leads to the accumulation of poorly soluble 2,8-dihydroxyadenine (DHA) in the kidneys, resulting in a variety of renal presentations including nephrolithiasis, acute kidney injury, and chronic kidney disease (CKD) caused by crystal nephropathy. Here, we report a case of a 43-year-old man with 2,8-DHA crystalline nephropathy caused by APRT deficiency strongly suspected by renal biopsy results and definitively diagnosed by a urine gas chromatography-mass spectrometry (GC/MS)-based plasma metabolomic assessment. This case represents the importance of awareness and recognition of the signs and symptoms of this rare condition and its progression to CKD, which can be prevented by the early administration of xanthine oxidoreductase inhibitors.
MeSH term(s)	Male ; Humans ; Adult ; Adenine Phosphoribosyltransferase ; Urolithiasis/etiology ; Urolithiasis/complications ; Kidney Calculi/etiology ; Renal Insufficiency, Chronic/complications
Chemical Substances	Adenine Phosphoribosyltransferase (EC 2.4.2.7)
Language	English
Publishing date	2022-12-28
Publishing country	Japan
Document type	Case Reports ; Journal Article
ZDB-ID	2660492-9
ISSN	2192-4449 ; 2192-4449
ISSN (online)	2192-4449
ISSN	2192-4449
DOI	10.1007/s13730-022-00768-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Mepolizumab administration for eosinophilic granulomatosis with polyangiitis in an elderly patient with abrupt onset of limb ischemia and peripheral neuropathy: A case-based literature review.

Terashima, Seika / Yamaguchi, Makoto / Ishihara, Tomomi / Hagita, Junichiro / Katsuno, Takayuki / Ito, Mayumi / Sugiyama, Hirokazu / Iwagaitsu, Shiho / Nobata, Hironobu / Kinashi, Hiroshi / Ishimoto, Takuji / Banno, Shogo / Ito, Yasuhiko

Modern rheumatology case reports

2022

Abstract: Eosinophilic granulomatosis with polyangiitis is a type of anti-neutrophil cytoplasmic antibody-associated vasculitis characterized by small- to medium-sized vessel vasculitis and is typically associated with eosinophilic granulomatous inflammation. ... ...

Abstract	Eosinophilic granulomatosis with polyangiitis is a type of anti-neutrophil cytoplasmic antibody-associated vasculitis characterized by small- to medium-sized vessel vasculitis and is typically associated with eosinophilic granulomatous inflammation. Eosinophilic granulomatosis with polyangiitis can affect any organ system, most commonly the lungs, skin, and nervous system. However, limb ulcers are rare complications and have only been described in few case reports. Furthermore, no documented cases of eosinophilic granulomatosis with polyangiitis have been treated with mepolizumab. Herein, we report a case of an 86 year-old Japanese woman with anti-neutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis, who had an abrupt onset of upper limb ulcers and bilateral foot drop due to multiple mononeuropathy. Clinicopathological sural nerve biopsy showed eosinophil-associated vascular damage. The patient was administered steroids, intravenous immunoglobulin, vasodilators, and mepolizumab; this resulted in clinical improvement of her finger ulcers and peripheral neuropathy without any adverse effects. In cases of abrupt onset of limb ischemia and peripheral neuropathy, physicians should consider the possibility of eosinophilic granulomatosis with polyangiitis as a differential diagnosis. Furthermore, early administration of mepolizumab might yield better outcomes in terms of improving limb ischemia and peripheral neuropathy.
Language	English
Publishing date	2022-09-15
Publishing country	England
Document type	Journal Article
ISSN	2472-5625
ISSN (online)	2472-5625
DOI	10.1093/mrcr/rxac073
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED